Sodium Oxybate Patent Expiration
Sodium Oxybate is Used for treating patients with narcolepsy and reducing excessive daytime sleepiness and cataplexy when administered with specific medications. It was first introduced by Jazz Pharmaceuticals Inc
Sodium Oxybate Patents
Given below is the list of patents protecting Sodium Oxybate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lumryz | US11779557 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Mar 16, 2042 | Avadel Cns |
| Lumryz | US11583510 | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal | Feb 07, 2042 | Avadel Cns |
| Lumryz | US10925844 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state | Feb 28, 2040 | Avadel Cns |
| Lumryz | US10272062 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US10736866 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US10952986 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US10973795 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11000498 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11052061 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11065224 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11400065 | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11504347 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11602512 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11602513 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11766418 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11826335 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11839597 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11896572 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US11986451 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US12097175 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US12097176 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US12109186 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US12115142 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US12115143 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US12115144 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Lumryz | US12115145 | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | Jul 21, 2037 | Avadel Cns |
| Xyrem |
US10213400 (Pediatric) | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Sep 15, 2033 | Jazz Pharms |
| Xyrem |
US10864181 (Pediatric) | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Sep 15, 2033 | Jazz Pharms |
| Xyrem |
US11253494 (Pediatric) | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Sep 15, 2033 | Jazz Pharms |
| Xyrem |
US8772306 (Pediatric) | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Sep 15, 2033 | Jazz Pharms |
| Xyrem |
US9050302 (Pediatric) | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Sep 15, 2033 | Jazz Pharms |
| Xyrem |
US9486426 (Pediatric) | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Sep 15, 2033 | Jazz Pharms |
| Xyrem | US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Mar 15, 2033 | Jazz Pharms |
| Xyrem | US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Mar 15, 2033 | Jazz Pharms |
| Xyrem | US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Mar 15, 2033 | Jazz Pharms |
| Xyrem | US11986446 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Mar 15, 2033 | Jazz Pharms |
| Xyrem | US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Mar 15, 2033 | Jazz Pharms |
| Xyrem | US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Mar 15, 2033 | Jazz Pharms |
| Xyrem | US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | Mar 15, 2033 | Jazz Pharms |
| Xyrem |
US7668730 (Pediatric) | Sensitive drug distribution system and method |
Dec 16, 2024
(Expired) | Jazz Pharms |
| Xyrem |
US7765106 (Pediatric) | Sensitive drug distribution system and method |
Dec 16, 2024
(Expired) | Jazz Pharms |
| Xyrem |
US7765107 (Pediatric) | Sensitive drug distribution system and method |
Dec 16, 2024
(Expired) | Jazz Pharms |
| Xyrem | US7668730 | Sensitive drug distribution system and method |
Jun 16, 2024
(Expired) | Jazz Pharms |
| Xyrem | US7765106 | Sensitive drug distribution system and method |
Jun 16, 2024
(Expired) | Jazz Pharms |
| Xyrem | US7765107 | Sensitive drug distribution system and method |
Jun 16, 2024
(Expired) | Jazz Pharms |
| Xyrem |
US7895059 (Pediatric) | Sensitive drug distribution system and method |
Jun 17, 2023
(Expired) | Jazz Pharms |
| Xyrem |
US8457988 (Pediatric) | Sensitive drug distribution system and method |
Jun 17, 2023
(Expired) | Jazz Pharms |
| Xyrem |
US8589182 (Pediatric) | Sensitive drug distribution system and method |
Jun 17, 2023
(Expired) | Jazz Pharms |
| Xyrem |
US8731963 (Pediatric) | Sensitive drug distribution system and method |
Jun 17, 2023
(Expired) | Jazz Pharms |
| Xyrem | US7895059 | Sensitive drug distribution system and method |
Dec 17, 2022
(Expired) | Jazz Pharms |
| Xyrem | US8457988 | Sensitive drug distribution system and method |
Dec 17, 2022
(Expired) | Jazz Pharms |
| Xyrem | US8589182 | Sensitive drug distribution system and method |
Dec 17, 2022
(Expired) | Jazz Pharms |
| Xyrem | US8731963 | Sensitive drug distribution system and method |
Dec 17, 2022
(Expired) | Jazz Pharms |
| Xyrem |
US6780889 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan 04, 2021
(Expired) | Jazz Pharms |
| Xyrem |
US7262219 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan 04, 2021
(Expired) | Jazz Pharms |
| Xyrem | US6780889 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul 04, 2020
(Expired) | Jazz Pharms |
| Xyrem | US7262219 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul 04, 2020
(Expired) | Jazz Pharms |
| Xyrem |
US7851506 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun 22, 2020
(Expired) | Jazz Pharms |
| Xyrem |
US8263650 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun 22, 2020
(Expired) | Jazz Pharms |
| Xyrem |
US8324275 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun 22, 2020
(Expired) | Jazz Pharms |
| Xyrem |
US8859619 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun 22, 2020
(Expired) | Jazz Pharms |
| Xyrem |
US8952062 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun 22, 2020
(Expired) | Jazz Pharms |
| Xyrem |
US9539330 (Pediatric) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun 22, 2020
(Expired) | Jazz Pharms |
| Xyrem | US7851506 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec 22, 2019
(Expired) | Jazz Pharms |
| Xyrem | US8263650 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec 22, 2019
(Expired) | Jazz Pharms |
| Xyrem | US8324275 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec 22, 2019
(Expired) | Jazz Pharms |
| Xyrem | US8859619 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec 22, 2019
(Expired) | Jazz Pharms |
| Xyrem | US8952062 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec 22, 2019
(Expired) | Jazz Pharms |
| Xyrem | US9539330 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec 22, 2019
(Expired) | Jazz Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sodium Oxybate's patents.
Latest Legal Activities on Sodium Oxybate's Patents
Given below is the list recent legal activities going on the following patents of Sodium Oxybate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2024 | US10864181 |
| Maintenance Fee Reminder Mailed Critical | 29 Apr, 2024 | US8263650(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Apr, 2024 | US9486426 |
| Expire Patent Critical | 27 Mar, 2023 | US7895059(Litigated) |
| Expire Patent Critical | 20 Mar, 2023 | US8952062(Litigated) |
| Expire Patent Critical | 16 Jan, 2023 | US7851506(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Nov, 2022 | US9050302(Litigated) |
| Expire Patent Critical | 21 Nov, 2022 | US8859619(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 10 Oct, 2022 | US7895059(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 03 Oct, 2022 | US8952062(Litigated) |
Sodium Oxybate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Sodium Oxybate Generic API Manufacturers
Only one generic application has been filed for Sodium Oxybate.
Given below is the list of companies who have filed for Sodium Oxybate generic, along with the locations of their manufacturing plants worldwide.
1. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Sodium Oxybate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5GM/ML | solution | Discontinued | ORAL | N/A | Jan 17, 2017 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||